Carbidopa Tablet
NDC Package 42799-123-01

11-digit billing NDC: 42799012301 · Billing unit: EA · 100 EA per package

Package Information

Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.Carbidopa tablets are for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa tablets provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.Carbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa-levodopa necessitates separate titration of each medication.Carbidopa tablets are used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. This formulation utilizes a tablet delivery system. Marketed by Edenbridge Pharmaceuticals Llc., this product is identified by NDC 42799-123 and is authorized under FDA application ANDA205304.

Identification & Billing

NDC Package Code
42799-123-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
42799012301
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
RxCUI: 260260 - carbidopa 25 MG Oral Tablet

Clinical Specifications

Proprietary Name
Carbidopa
Non-Proprietary Name
Carbidopa
Substance Name
Carbidopa
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.Carbidopa tablets are for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa tablets provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.Carbidopa tablets are for use with levodopa in the occasional patient whose dosage requirement of carbidopa-levodopa necessitates separate titration of each medication.Carbidopa tablets are used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa.Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa tablets permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.Certain patients who responded poorly to levodopa alone have improved when carbidopa-levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa tablets on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.In deciding whether to give carbidopa tablets with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.

Regulatory & Marketing

Labeler Name
Edenbridge Pharmaceuticals Llc.
Product Type
Human Prescription Drug
FDA Application #
ANDA205304
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-19-2016
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (42799-123). Click a package code to view its specific billing and regulatory data.

1000 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42799-123-01 identifies a specific commercial package of 100 tablet in 1 bottle of Carbidopa, a human prescription drug labeled by Edenbridge Pharmaceuticals Llc.. This tablet is formulated for oral use and contains carbidopa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Edenbridge Pharmaceuticals Llc. on February 19, 2016. The current certification is valid through December 31, 2026.

How is this Edenbridge Pharmaceuticals Llc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42799012301. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42799-123-01
11-Digit CMS (5-4-2)
42799-0123-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.